Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.

Literature DB >> 19528274

In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.

Andrea Endimiani, Yuvraj Choudhary, Robert A Bonomo.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2009 PMID： 19528274 PMCID： PMC2715587 DOI： 10.1128/AAC.00641-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

9 in total

1. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.

Authors: Alain Bonnefoy; Claudine Dupuis-Hamelin; Valérie Steier; Carole Delachaume; Catherine Seys; Thérèse Stachyra; Monique Fairley; Michèle Guitton; Maxime Lampilas
Journal: J Antimicrob Chemother Date: 2004-07-14 Impact factor: 5.790

2. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.

Authors: Andrea Endimiani; Lenore L Carias; Andrea M Hujer; Christopher R Bethel; Kristine M Hujer; Federico Perez; Rebecca A Hutton; William R Fox; Geraldine S Hall; Michael R Jacobs; David L Paterson; Louis B Rice; Stephen G Jenkins; Fred C Tenover; Robert A Bonomo
Journal: Antimicrob Agents Chemother Date: 2008-04-21 Impact factor: 5.191

3. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors: Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal: J Antimicrob Chemother Date: 2005-05-25 Impact factor: 5.790

4. Detection of plasmid-mediated KPC-producing Klebsiella pneumoniae in Ottawa, Canada: evidence of intrahospital transmission.

Authors: David Goldfarb; Sarah-Beth Harvey; Kelsi Jessamine; Peter Jessamine; Baldwin Toye; Marc Desjardins
Journal: J Clin Microbiol Date: 2009-04-08 Impact factor: 5.948

5. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

Authors: David M Livermore; Shazad Mushtaq; Marina Warner; Christine Miossec; Neil Woodford
Journal: J Antimicrob Chemother Date: 2008-08-09 Impact factor: 5.790

Review 6. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

Authors: Patrice Nordmann; Gaelle Cuzon; Thierry Naas
Journal: Lancet Infect Dis Date: 2009-04 Impact factor: 25.071

7. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA.

Authors: Andrea Endimiani; Andrea M Hujer; Federico Perez; Christopher R Bethel; Kristine M Hujer; Jennifer Kroeger; Margret Oethinger; David L Paterson; Mark D Adams; Michael R Jacobs; Daniel J Diekema; Gerri S Hall; Stephen G Jenkins; Louis B Rice; Fred C Tenover; Robert A Bonomo
Journal: J Antimicrob Chemother Date: 2009-01-20 Impact factor: 5.790

Review 8. Novel beta-lactam antibiotics and inhibitor combinations.

Authors: Matteo Bassetti; Elda Righi; Claudio Viscoli
Journal: Expert Opin Investig Drugs Date: 2008-03 Impact factor: 6.206

9. Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil.

Authors: Gisele Peirano; Liliane M Seki; Vera Lúcia Val Passos; Maria Cristina F G Pinto; Lília R Guerra; Marise D Asensi
Journal: J Antimicrob Chemother Date: 2008-11-20 Impact factor: 5.790

9 in total

47 in total

1. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Authors: Thérèse Stachyra; Marie-Claude Péchereau; Jean-Michel Bruneau; Monique Claudon; Jean-Marie Frère; Christine Miossec; Kenneth Coleman; Michael T Black
Journal: Antimicrob Agents Chemother Date: 2010-10-04 Impact factor: 5.191

2. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors: Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2011-04-25 Impact factor: 5.191

3. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors: Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal: Antimicrob Agents Chemother Date: 2014-03-31 Impact factor: 5.191

4. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors: Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal: Antimicrob Agents Chemother Date: 2018-06-26 Impact factor: 5.191